Condition
Tuberous Sclerosis Complex
ClinicalTrials.gov condition label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 41 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
41 shownA Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) GuidelinesNCT07561957 · 2026-01-14
RECRUITINGTuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)NCT06160310 · 2023-07-01
RECRUITINGPlacebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis ComplexNCT05534672 · 2023-01-23
RECRUITINGStopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention StudyNCT05104983 · 2021-10-13
RECRUITINGSafety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)NCT07680322 · 2026-09-01
NOT_YET_RECRUITINGEpidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALYNCT05485831 · 2025-02-24
ACTIVE_NOT_RECRUITINGAstroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type IINCT06392009 · 2024-07-10
ACTIVE_NOT_RECRUITINGClinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSCNCT05495425 · 2022-06-01
COMPLETEDLymphangioleiomyomatosis, a Study on Cathepsin KNCT05323370 · 2022-05-31
COMPLETEDOpen-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related EpilepsyNCT05604170 · 2022-05-16
TERMINATEDAdjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related EpilepsyNCT05323734 · 2022-04-01
COMPLETEDBasimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSCNCT05059327 · 2022-03-03
COMPLETEDFeasibility of [11C]Acetate-PET in LAM and TSCNCT05467397 · 2021-08-30
ACTIVE_NOT_RECRUITINGAcceptance and Commitment Therapy in Tuberous Sclerosis ComplexNCT05867576 · 2021-08-12
UNKNOWNAssessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral SolutionNCT05044819 · 2021-07-07
ACTIVE_NOT_RECRUITINGEfficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in InfantsNCT04987463 · 2021-05-07
UNKNOWNStopping TSC Onset and Progression 2: Epilepsy Prevention in TSC InfantsNCT04595513 · 2020-09-08
COMPLETEDThe Effectiveness and Safety of Resective Epilepsy Surgery for TRENCT04198181 · 2019-12-12
ACTIVE_NOT_RECRUITINGThe Effectiveness and Safety of Vagus Nerve Stimulation for TRENCT04198207 · 2019-12-10
COMPLETEDDermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation RelationshipNCT04112537 · 2019-03-01
UNKNOWNAspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis ComplexNCT03356769 · 2017-11-20
UNKNOWNRoll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentNCT02962414 · 2017-08-23
ACTIVE_NOT_RECRUITINGPreventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis ComplexNCT02849457 · 2016-12-01
COMPLETEDAn Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)NCT02544750 · 2016-08-31
COMPLETEDPredicting Epileptogenic Tubers in Patients with Tuberous Sclerosis ComplexNCT06789419 · 2016-07-01
COMPLETEDStudies in Patients With Tuberous Sclerosis ComplexNCT03276195 · 2016-05-01
COMPLETEDA Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)NCT02544763 · 2016-04-06
COMPLETEDEarly Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis ComplexNCT02687633 · 2015-09-01
COMPLETEDClinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of FranceNCT02887781 · 2015-08-13
UNKNOWNThe Cognitive Variability in NF1 and TSC Monozygotic TwinsNCT02436746 · 2015-04-01
UNKNOWNEverolimus for Cancer With TSC1 or TSC2 MutationNCT02201212 · 2014-09-01
COMPLETEDSafety of Simvastatin in LAM and TSCNCT02061397 · 2014-03-01
COMPLETEDA Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCDNCT02451696 · 2014-01-01
COMPLETEDLong-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis ComplexNCT02098759 · 2013-11-01
UNKNOWNRapalogues for Autism Phenotype in TSC: A Feasibility StudyNCT01929642 · 2013-07-01
COMPLETEDEarly Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)NCT01780441 · 2013-01-01
COMPLETEDEfficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis ComplexNCT01730209 · 2012-11-01
UNKNOWNPotential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSCNCT01767779 · 2012-09-01
COMPLETEDTrial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)NCT01289912 · 2011-01-01
COMPLETEDEverolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)NCT01070316 · 2010-01-01
COMPLETEDTuberous Sclerosis Complex Natural History Study: Renal ManifestationsNCT00598455 · 2008-02-01
COMPLETEDCommon interventions
PlaceboDRUG8EverolimusDRUG6GanaxoloneDRUG2GWP42003-PDRUG2SirolimusDRUG2[11C]acetateDRUG124h urineOTHER1Acceptance and Commitment Therapy (ACT)BEHAVIORAL1AEDDRUG1AspirinDRUG1AV078DRUG1Basimglurant with crossover to PlaceboDRUG1CannabidiolDRUG1Delayed Vigabatrin (Placebo)DRUG1Early VigabatrinDRUG1Epidiolex 100 mg/mL Oral SolutionDRUG1epilepsy early diagnosis protocolDEVICE1Everolimus Oral ProductDRUG1JASPERBEHAVIORAL1NPC-12Y gelDRUG1NPC-12Y placebo gelDRUG1PlaceboOTHER1Placebo with crossover to BasimglurantDRUG1RAD001DRUG1RadiprodilDRUG1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Jazz Pharmaceuticals
4
Beijing Children's Hospital
3
Children's Hospital Medical Center, Cincinnati
3
Erasmus Medical Center
2
Katarzyna Kotulska
2
Marinus Pharmaceuticals
2
Aeovian Pharmaceuticals, Inc.
1
Boston Children's Hospital
1
Brigham and Women's Hospital
1
Dana-Farber Cancer Institute
1
Darcy Krueger
1
David M. Ritter
1
GRIN Therapeutics, Inc.
1
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
1
Martina Bebin
1
Trial status mix
COMPLETED21
UNKNOWN8
ACTIVE_NOT_RECRUITING6
RECRUITING4
NOT_YET_RECRUITING1
TERMINATED1
Phase mix
PHASE216
PHASE39
PHASE15
NA4
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.